Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.

Détails bibliographiques
Auteurs principaux:	Shipman, C, Croucher, P
Format:	Conference item
Publié:	2002

Documents similaires

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
par: Shipman, C, et autres
Publié: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
par: Croucher, P, et autres
Publié: (2000)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
par: Locklin, R, et autres
Publié: (2005)

Role of osteoprotegerin (OPG) in cancer.
par: Holen, I, et autres
Publié: (2006)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
par: Shipman, C, et autres
Publié: (2002)

Osteoprotegerin and the development of myeloma bone disease
par: Croucher, P, et autres
Publié: (2004)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
par: Croucher, P, et autres
Publié: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
par: Croucher, P, et autres
Publié: (2001)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
par: Locklin, R, et autres
Publié: (2007)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
par: Shipman, C, et autres
Publié: (2000)

Differential sensitivity of normal osteoblast-like cells and osteosarcoma cells to TRAIL and an agonist antibody to TRAIL receptor-2
par: Locklin, R, et autres
Publié: (2005)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
par: De Leenheer, E, et autres
Publié: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
par: Croucher, P, et autres
Publié: (2001)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
par: Holen, I, et autres
Publié: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
par: Eaton, C, et autres
Publié: (2004)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
par: Miles, L, et autres
Publié: (2004)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
par: Shipman, C, et autres
Publié: (1998)

APO in profile
par: 6818 Asian Productivity Organization (APO)
Publié: ([19-)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
par: Eaton, C, et autres
Publié: (2004)

Expression of TRAIL and TRAIL receptors in normal and malignant tissues.
par: Daniels, R, et autres
Publié: (2005)

Urban trails : a preliminary list of trails and sources/
par: 409605 Goodey, Brian
Publié: (1974)

Kafka's trail
par: McLees, F
Publié: (2020)

The Oregan trail /
par: 350759 Parkman, Francis
Publié: (1931)

The paradise trail /
par: Campbell, Duncan, author
Publié: (2008)

The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ɛ2.
par: Suri, S, et autres
Publié: (2013)

The forgotten APOE allele: A review of the evidence and suggested mechanisms for the protective effect of APOE e2
par: Suri, S, et autres
Publié: (2013)

Selective targeting of DR5 circumvents resistance of MG-63 osteosarcoma to trail-induced apoptosis
par: Locklin, R, et autres
Publié: (2006)

Gene-gene interaction between apo E and apo B in determining plasma levels of apo B-containing lipoproteins
par: Andersson, C, et autres
Publié: (1998)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
par: Vanderkerken, K, et autres
Publié: (2003)

Gene-gene interaction between apoB and apoE in determining plasma levels and heterogeneity of apoB-containing lipoproteins
par: Andersson, C, et autres
Publié: (1998)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
par: De Leenheer, E, et autres
Publié: (2004)

Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL.
par: Mongkolsapaya, J, et autres
Publié: (1998)

TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis
par: Singh, HD, et autres
Publié: (2017)

Physical impact indicators for mountain trails at Gunung Tahan Trail, Malaysia
par: Yaakob, Sam Shor Nahar
Publié: (2019)

Trailing Pahang’s heritage
par: Aisyah Hanum, Abu Bakar
Publié: (2010)

Eleven trails are illegal
par: Wahab, Farid, et autres
Publié: (2024)

The Cocaine trail [kasetvideo]
Publié: ([19-)

Trail driving days /
par: 376758 Brown, Dee Alexander
Publié: (1952)

Planning for urban trails/
par: 8697 American Society of Planning Officials, et autres
Publié: (1969)

Horse thief trail /
par: 327984 Richardson, Gladwell
Publié: ([s d)